Menu
Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Home
About Us
Subscribe
Subscribe Individual
Subscribe Biotech Premium (Corporate)
Premium Biotech Coverage
Current News
Special Features
Company Index
Index Table
Summit
19th Bioshares Biotech Summit
Summit History
Contact
Contact Us
Email Alerts
Categories
Categories
Actinogen (ACW)
Adalta (1AD)
Anteris Technologies (AVR)
Aroa Biosurgery (ARX)
Blinklab (BB1)
Blog
Botanix (BOT)
Chimeric Therapeutics (CHM)
Clever Culture Systems (CC5)
Clinuvel Pharmaceuticals (CUV)
Cogstate (CGS)
Dimerix (DXB)
Immuron (IMC)
Imugene (IMU)
Island Pharmaceuticals (ILA)
Neuren Pharmaceuticals (NEU)
Syntara (SNT) (previously Pharmaxis, PXS)
Uncategorized
January 28th, 2025
Wheels in Motion for Cogstate
Read More
January 28th, 2025
Solid Quarter for Somnomed; Revenue up 20% to $28.5 Million
Read More
January 9th, 2025
Dimerix Secures Third Licensing Deal
Read More
December 22nd, 2024
Anteris Completes Re-Domiciliation to US, Raises US$88 Million, Maintains Australian Listing
Read More
December 20th, 2024
Positive Phase I Final Data from Cynata Therapeutics
Read More
December 6th, 2024
Island Pharmaceuticals Achieves Endpoints in Phase 2a Study in Dengue Fever
Read More
December 5th, 2024
Blinklab Makes Further Improvements to Autism Diagnostic Ahead of Pivotal US Study
Read More
December 5th, 2024
Dimerix: Unmet Need Drives Positive Changes to Trial Endpoints in FSGS
Read More
October 29th, 2024
Cogstate Positioned for Top and Bottom Line Growth in FY2025
Read More
October 11th, 2024
Amplia Reaches Positive Endpoint After 16 Patients Treated
Read More
October 11th, 2024
Island's Shares Surge on Trial Start and Capital Raise
Read More
October 11th, 2024
Opthea Share Price Starts to Move Ahead of Phase III Trial Readouts Mid-2025
Read More
September 3rd, 2024
What's Next for Clinuvel Pharmaceuticals?
Read More
August 1st, 2024
Island Pharmaceuticals Update
Read More
August 1st, 2024
Summit Coverage: Neuren Pharmaceuticals Outlines Path Forward for NNZ-2591
Read More
August 1st, 2024
Neuren Pharmaceuticals Reports Positive Results in Third Indication - Angelman Syndrome
Read More
August 1st, 2024
Aroa Biosurgery - Moving to Cashflow Positive
Read More
July 10th, 2024
Botanix Raises $70 million with Sofdra FDA Approval
Read More
July 10th, 2024
Island Pharmaceuticals to In-License New Asset
Read More
July 10th, 2024
Clinuvel Pharmaceuticals Continues Expansion of Portfolio into Parkinson's Disease
Read More
Pages
1
2
3
4
5
6
7
8
9
